About
Incubate

About Incubate

Our Mission
Overview
Incubate is a 501(c)(4) organization of venture capital firms representing the patient, corporate, and investment communities. Our primary aim is to educate policymakers on the role of venture capital in bringing promising treatments to patients in need.
Mission
We help ensure patients continue to benefit from the unrelenting innovation spurred by venture capital investment in life sciences and protected by America’s intellectual property system.
Why venture capital matters
Learn why venture investment is so vital to developing effective new medical treatments.
Our Priorities

Foster innovation
Help ensure a level global playing field for investment and promote policies that empower life science innovators to build and grow in the United States.
Why It Matters
For America to remain the leader in medical innovation, its business, investment, and policy ecosystems must welcome and support life science innovators from start-ups to major firms.

Safeguard advancements
Strengthen and protect U.S. intellectual property provisions by promoting patent and regulatory systems that encourage life sciences innovation.
Why It Matters
Investment in life science is risky: 9 out of 10 initial treatments are ineffective or don’t recoup their development costs. Protecting the American intellectual property system preserves incentives for the development of new treatments and ensures that the revenue from successful treatments can subsidize continued innovation.

Amplify the results
Spotlight the venture capital-driven breakthroughs that are transforming medicine for patients and health professionals around the globe.
Why It Matters
Amidst the nuanced discussions around healthcare costs in this country, policymakers, providers, and patients all deserve a complete understanding of the factors that contribute to successful development of effective treatments.
Resources
Get valuable information on policy, venture capital, and the life sciences innovation ecosystem.
Our People
Incubate Board Members

Lindsay Androski
President

Janis Naeve
Treasurer
Advisory Board

Lindsay Androski
M.B.A, J.D.President and CEO,
Roivant Foundation
Roivant Sciences

Christine Brennan
Managing Director,
Vertex Venture HC

John Conrad
President & CEO,
Illinois Biotechnology Innovation Organization (iBIO)

Brian Darmody
CEO,
Association of University Research Parks (AURP)

Barbara Dalton
Ph.DVice President, WWBD and Senior Managing Partner,
Pfizer Ventures

Bart Forsyth
JDVice President,
Federal Advocacy
PhRMA

Gaurav Gupta
M.D., M.S.Managing Partner, Life Sciences Private Capital

Bryan Gutierrez
Principal, Gordian Ventures

Orin Herskowitz
Executive Director, Columbia Technology Ventures; SVP of Applied Innovation and Industry Partnerships, Columbia University

Adam Houghton
Ph.D., M.B.A.Chief Business Officer,
Upstream Bio

Chris Israel
M.B.ASenior Partner,
American Continental Group

Peter Kolchinsky
Ph.D.Managing Partner,
RA Capital Management;
Author of The Biotech Social Contract series on Medium

Gary Lauder
M.B.A.Managing Director,
Lauder Partners

Erin Mistry
EVP and Chief Commercial Officer,
Cormedix

Amy Millman
M.P.A.Founder, Springboard Enterprises

Janis Naeve
Ph.D.Partner
Cota Capital

Imran Nasrullah
M.S. J.DVP & US Head,
Collaborate2Cure Hub, Bayer

Sara Nayeem
M.D.Partner,
Avoro Ventures

Emily Roberts
Director,
Issue Advocacy
Genentech

Nancy Sullivan
CEO and Managing Director,
Illinois Ventures

Karla Talanian
M.S., M.B.A.Senior Director of Life Sciences Apprenticeships,
MassBio

Matt Tremblay
Chief Executive Officer, Blackbird Laboratories

Rose Wang
M.B.A.Executive Advisor,
AIM-HI Accelerator Fund; Founder & CEO 1104Health

Jonathan Weinberger
J.D., M.A.Chief Advocate,
Global Transportation Technology Policy

Peter Young
M.B.A.Life Science Executive & Venture Partner,
Pappas Capital
Our Team

John Stanford
Executive Director

Ashlyn Roberts
Coalition Director

Maggie Ambrose
Manager

Grace Moster
Senior Associate, Communications